Follistatin 344 vs RAD-140 (Testolone)
A side-by-side research comparison of Follistatin 344 and RAD-140 (Testolone) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Follistatin 344 | RAD-140 (Testolone) |
|---|---|---|
| Full name | Follistatin 344 (FST-344) | Testolone (RAD-140) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Investigational (not approved; banned in sport) |
| Mechanism | Binds myostatin and activin A with high affinity, preventing ActRIIB receptor activation. Removes the brake on muscle growth allowing uninhibited satellite cell proliferation. | Acts as a strong, tissue-selective androgen receptor agonist in muscle and bone, driving anabolic signaling with a higher anabolic-to-androgenic ratio than testosterone in preclinical models. |
| Molecular weight | 36,000 Da | 393.83 Da |
| Half-life | 2-4 hours | ~16-20 hours |
| Bioavailability | Moderate (SubQ) | Oral |
| Typical dose | 100-200 mcg | Commonly cited 5-15 mg/day (research) |
| Frequency | Daily for 10-30 days | Once daily |
| Route | Subcutaneous | Oral |
Follistatin 344 reported benefits
- Significant muscle growth
- Myostatin inhibition
- Increased strength
- Activin neutralization
- Enhanced recovery
RAD-140 (Testolone) reported benefits
- Strong lean muscle gains (research)
- Increased strength
- Studied originally for muscle wasting and breast cancer
- Bone-supportive signaling
Related comparisons
Research and educational reference only. Not medical advice.